Clinical Trials Logo

Raynaud Phenomenon clinical trials

View clinical trials related to Raynaud Phenomenon.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03869008 Terminated - Raynaud Phenomenon Clinical Trials

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of vasospasm of the digital arteries in addition to significant impairment of quality of life. It is well known that cold exposure precipitates episodes of RP, but the mechanism for cold sensitivity is not known, and treatment of RP is not satisfactory to the patients and their physicians. The goal in this study is to test the possibility that non invasive vagus nerve stimulation (nVNS) with gammaCore which is already approved by the FDA for headaches and migraines may be an effective and well tolerated therapy for Raynaud's Phenomenon.

NCT ID: NCT03639766 Terminated - Raynaud Phenomenon Clinical Trials

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

Start date: August 31, 2018
Phase: Phase 4
Study type: Interventional

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.